New Leadership Appointments at RVL Pharmaceuticals
RVL Pharmaceuticals, Inc and its partners have made significant leadership changes designed to enhance the company's growth and drive the performance of their flagship product, Upneeq. The recent appointments are aimed at creating robust strategies for expanding market reach while ensuring that healthcare professionals and consumers are engaged effectively.
Lori Deo Takes the Helm as CEO
The Board has selected Lori Deo as Chief Executive Officer of RVL. Lori previously served as Executive Chairwoman, and the transition shows a clear commitment to continuity and a deeper connection with the company's vision moving forward. With extensive experience in managing global healthcare brands such as Johnson & Johnson and Pfizer, she is well-equipped to lead RVL in its ambitious growth plans. Under Lori's leadership, the company will focus on enhancing its positioning in the market, particularly through strategies that cater directly to healthcare professionals.
Amy Shah Appointed Chief Growth Officer
Amy Shah has also been brought on board as Chief Growth Officer. Known for her transformative contributions within the industry, Amy's deep-rooted expertise in constructing growth strategies and managing high-performance teams will play a pivotal role in RVL's commercial success. Her tenure at Johnson & Johnson has demonstrated her capacity to innovate and reshape consumer engagement through effective technology-driven solutions. Now, as CGO, she will oversee the integration of commercial functions, encompassing sales, marketing, and innovation initiatives.
Key Focus on Upneeq®
The driving force behind RVL's growth strategy is Upneeq®, the first FAA-approved eye drop designed to treat acquired ptosis. The company aims to maximize the market potential of Upneeq®, projected to reach a Total Addressable Market (TAM) of approximately $2.5 billion. Lori Deo expressed strong confidence in their strategy, emphasizing the importance of consumer engagement and healthcare provider collaboration in reaching this expansive market.
Strong Commercial Performance
Data indicates that Upneeq® has been gaining remarkable traction, with revenues in Q3 indicating a 22% increase compared to Q3 of the previous year. This upward trend exemplifies the effectiveness of RVL's commercial strategies, as highlighted by Katerina Gembarski, Chief Financial Officer.
Understanding Upneeq®
Upneeq® is an innovative prescription eyedrop that provides a non-surgical solution to people experiencing low-lying eyelids. This product functions by stimulating a muscle in the eyelid, elevating the lid to achieve a more alert, open appearance. Notably, patients can expect visible results within just five minutes, and the effects can last for approximately eight hours.
Warnings and Precautions with Upneeq®
Despite its benefits, Upneeq® may pose certain health risks. Individuals with conditions such as heart disease, high or low blood pressure, or those experiencing dry mouth should consult their healthcare provider. It is crucial to understand how to use Upneeq® correctly to avoid contamination or increased eye pressure, particularly in users with narrow-angle glaucoma.
About RVL Pharmaceuticals
RVL Pharmaceuticals is at the forefront of integrating digital advancements within its commercial processes, from product acquisition to customer fulfillment. With a keen focus on meeting the needs of both consumers and healthcare providers, RVL aims to reshape the marketplace.
Partnership with Athyrium Capital Management
RVL benefits from its association with Athyrium Capital Management, a specialized asset management firm focused on healthcare investment opportunities. This partnership enhances RVL's capacity to navigate the evolving pharmaceutical landscape, leveraging over $4.6 billion in committed capital to fuel its growth and innovation.
Frequently Asked Questions
What is the goal of RVL's new leadership appointments?
The new leadership aims to enhance RVL's growth potential and commercial strategies, particularly for Upneeq®.
Who is Lori Deo?
Lori Deo is the newly appointed Chief Executive Officer of RVL Pharmaceuticals, previously serving as Executive Chairwoman.
What is Upneeq® used for?
Upneeq® is an FDA-approved prescription eye drop designed to treat acquired ptosis or low-lying eyelids.
How has Upneeq® performed commercially?
Upneeq® has experienced strong commercial growth, with a reported 22% revenue increase in Q3 year over year.
What should patients know before using Upneeq®?
Patients should be aware of potential health risks and consult healthcare providers regarding specific conditions that may necessitate caution.
